1 false false false false false false false false false false true false false false false false false No description of principal activity 2023-05-01 Sage Accounts Production Advanced 2024 - FRS102_2024 2,241 2,241 560 560 1,681 xbrli:pure xbrli:shares iso4217:GBP 12572778 2023-05-01 2024-04-30 12572778 2024-04-30 12572778 2023-04-30 12572778 2022-05-01 2023-04-30 12572778 2023-04-30 12572778 2022-04-30 12572778 bus:Director1 2023-05-01 2024-04-30 12572778 core:WithinOneYear 2024-04-30 12572778 core:WithinOneYear 2023-04-30 12572778 core:ShareCapital 2024-04-30 12572778 core:ShareCapital 2023-04-30 12572778 core:RetainedEarningsAccumulatedLosses 2024-04-30 12572778 core:RetainedEarningsAccumulatedLosses 2023-04-30 12572778 bus:Director1 2023-04-30 12572778 bus:Director1 2024-04-30 12572778 bus:Director1 2022-04-30 12572778 bus:Director1 2023-04-30 12572778 bus:Director1 2022-05-01 2023-04-30 12572778 bus:SmallEntities 2023-05-01 2024-04-30 12572778 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 12572778 bus:SmallCompaniesRegimeForAccounts 2023-05-01 2024-04-30 12572778 bus:EntityHasNeverTraded 2023-05-01 2024-04-30 12572778 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 12572778 bus:FullAccounts 2023-05-01 2024-04-30 12572778 core:OfficeEquipment 2023-05-01 2024-04-30 12572778 core:OfficeEquipment 2024-04-30
COMPANY REGISTRATION NUMBER: 12572778
MistryPharm Limited
Filleted Unaudited Financial Statements
Year ended
30 April 2024
MistryPharm Limited
Financial Statements
Year ended 30 April 2024
Contents
Page
Statement of financial position
1
Notes to the financial statements
3
MistryPharm Limited
Statement of Financial Position
30 April 2024
2024
2023
Note
£
£
£
£
Fixed assets
Tangible assets
5
1,681
Current assets
Debtors
6
937
41
Cash at bank and in hand
19,026
17,308
--------
--------
19,963
17,349
Creditors: amounts falling due within one year
7
1,983
3,071
--------
--------
Net current assets
17,980
14,278
--------
--------
Total assets less current liabilities
19,661
14,278
--------
--------
Capital and reserves
Called up share capital
10
10
Profit and loss account
19,651
14,268
--------
--------
Shareholders funds
19,661
14,278
--------
--------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
MistryPharm Limited
Statement of Financial Position (continued)
30 April 2024
These financial statements were approved by the board of directors and authorised for issue on 27 February 2025 , and are signed on behalf of the board by:
Mr S Mistry
Director
Company registration number: 12572778
MistryPharm Limited
Notes to the Financial Statements
Year ended 30 April 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 7 Whitehall Road West, Birkenshaw, Bradford, BD11 2LS, England.
2. Statement of compliance
These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
(a) Basis of preparation
The financial statements have been prepared on the historical cost basis. The financial statements are prepared in sterling, which is the functional currency of the entity.
(b) Going concern
The UK economy has recently been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company's trading results to a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
(c) Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts and of Value Added Tax. Revenue from the sale of goods is recognised when the sales invoice is issued.
(d) Current tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
(e) Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
(f) Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Equipment
-
25% reducing balance
(g) Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
(h) Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2023: 1 ).
5. Tangible assets
Equipment
£
Cost
At 1 May 2023
Additions
2,241
-------
At 30 April 2024
2,241
-------
Depreciation
At 1 May 2023
Charge for the year
560
-------
At 30 April 2024
560
-------
Carrying amount
At 30 April 2024
1,681
-------
At 30 April 2023
-------
6. Debtors
2024
2023
£
£
Other debtors
937
41
----
----
7. Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
880
849
Corporation tax
1,103
2,222
-------
-------
1,983
3,071
-------
-------
8. Director's advances, credits and guarantees
During the year the director entered into the following advances and credits with the company:
2024
Balance brought forward
Advances/ (credits) to the director
Amounts repaid
Balance outstanding
£
£
£
£
Mr S Mistry
41
2,209
( 1,312)
938
----
-------
-------
----
2023
Balance brought forward
Advances/ (credits) to the director
Amounts repaid
Balance outstanding
£
£
£
£
Mr S Mistry
1,072
1,281
( 2,312)
41
-------
-------
-------
----
The overdrawn loan account balance was repaid by dividends of £1,000 voted in January 2024 and £1,000 in January 2025.